Medical researchers have found that people who take the semaglutide-based drugs Ozempic and Wegovy may be less likely to die ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks to ...

The group of $1 trillion market cap stocks is tiny, and pharmaceutical giant Eli Lilly (NYSE: LLY) isn't a member yet, though ...

The controversy surrounding Ozempic, a popular diabetes medication turned weight-loss solution, has exploded as victims of severe side effects unite to file lawsuits against its manufacturers, Novo ...

Three IPOs each raised at least $100 million this week, in a welcome bump in activity. Read more here.

Investors have circled back to healthcare stocks this year, and they’re likely to stick around. If they came for the ...

Today, the company still remains wholly-owned by Wilson & Mensah. Aarti Shah is Senior Vice President and Chief Information ...

Thousands of plaintiffs have sued Ozempic manufacturers for failing to warn them about the risk of stomach paralysis.

The agency converted a prior accelerated approval to a traditional approval based on results from the LIBRETTO-531 trial.

On Thursday, Eli Lilly And Co (LLY) stock saw a decline, ending the day at $909.32 which represents a decrease of $-15.24 or -1.65% from the prior close of $924.56. The stock opened at $920.26 and ...

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...